Chemotherapy for non-small cell lung cancer: split-dose administration of Cisplatin over four consecutive days and Vinorelbine ditartrate
Furugaki, K.; Yoshida, J.; Ogawa, R.; Nagamatsu, I.; Miura, M.; Hokazono, K.; Umeda, S.; Shinohara, M.; Ekimura, M.; Ishimaru, T.; Okamoto, Y.; Ogami, N.; Nagaoka, S.; Ebe, K.; Emoto, T.; Seto, A.; Sugihara, M.; Yukawa, J.; Matsuo, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(2): 259-263
2009
ISSN/ISBN: 0385-0684 PMID: 19223742 Document Number: 629180
At present, combination chemotherapy with Cisplatin (CDDP) and Vinorelbine ditartrate (VNR) is one of the standard regimens for non-small cell lung cancer (NSLC). To avoid renal damage by CDDP, hydration and diuretic are indicated. But elderly/postoperative patients who have reduced lung vessel capacity are a high-risk group for pulmonary edema/right heart failure by hydration. In our hospital, CDDP is administered on four consecutive days without large hydration. CDDP: 80 mg/m2 (over four consecutive days)without large hydration+VNR: 20 mg/m2 was administered 30 NSLC patients(Stage III A & IV). Serum concentration of CDDP was monitored. Response rate was CR: 0 case; PR: 9 cases; SD: 16 cases; PD: 5 cases. Mean survival time (MST) was 292 days. The efficacy and prognosis are equivalent to a conventional CDDP+VNR regimen. On the other hand, side effects were reduced; neutrocytopenia (> Grade 3): 17%, renal dysfunction (>Grade 1): 17%. Mean serum concentrations of CDDP were accumulated day by day, 0.91 microg/mL(Day 1), 2.44 microg/mL(Day 4), but were all under the toxic threshold(8 microg/mL). Our regimen (CDDP given over four consecutive days without large hydration) may become a regimen for the high-risk patient.